McN-JR 4749
McN-JR 4749 Brand names, McN-JR 4749 Analogs
McN-JR 4749 Brand Names Mixture
- No information avaliable
McN-JR 4749 Chemical_Formula
C10H16NO+
McN-JR 4749 RX_link
http://www.rxlist.com/cgi/generic3/edrophonium.htm
McN-JR 4749 fda sheet
McN-JR 4749 msds (material safety sheet)
McN-JR 4749 Synthesis Reference
No information avaliable
McN-JR 4749 Molecular Weight
166.24 g/mol
McN-JR 4749 Melting Point
No information avaliable
McN-JR 4749 H2O Solubility
Appreciable as liquid hydrochloride salt
McN-JR 4749 State
Liquid
McN-JR 4749 LogP
-2.95
McN-JR 4749 Dosage Forms
Liquid for injection
McN-JR 4749 Indication
For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.
McN-JR 4749 Pharmacology
Edrophonium is a short and rapid-acting anticholinesterase drug. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium's pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Muscarinic receptors are found throughout the body, especially on muscle. Stimulation of these receptors causes to muscle contraction. In myasthenia gravis the body's immune system destroys many of the muscarinic receptors, so that the muscle becomes less responsive to nervous stimulation. Edrophonium chloride increases the amount of acetylcholine at the nerve endings. Increased levels of acetyl choline allow the remaining receptors to function more efficiently.
McN-JR 4749 Absorption
Rapidly absorbed.
McN-JR 4749 side effects and Toxicity
With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).
McN-JR 4749 Patient Information
No information avaliable
McN-JR 4749 Organisms Affected
Humans and other mammals
